New COVID-19 pill triggers clinical trials at Immokalee

IMMOKALEE, Florida – Pharmaceutical company Merck says its new COVID-19 pill halved the number of COVID-19-related hospitalizations and deaths during its studies.

Researchers say the first results show that patients who took the drug within five days of COVID symptoms appearing had about half the rate of hospitalizations and deaths as patients who took the placebo.

Company says it is testing the pill on 1,332 people in hopes of gaining federal approval on what some health officials
as Dr Christian Ramers calls the holy grail.

“The Holy Grail has always been an oral antiviral,” said Ramers of Family Health Centers in San Diego.

Merck says they are in the final stages of human trials and will soon be asking health authorities around the world to authorize the use of the pill.

Dr Ramers says a strong pill has always been the goal.

“What we wanted from the start was something easy, in pill form that we could use very quickly, like we use Tamivir, which is an oral antiviral agent for the flu,” he said. declared.

The drug is called Molnupiravir, and what it basically does is stop COVID-19 from replicating inside your body.

“It’s like throwing an adjustable wrench into the machinery to stop this virus from reproducing and really buy time for our own immune system to take over and kill the virus,” Ramers said.

A few doctors at Immokalee say they are enrolling patients in clinical trials.

Participants must be at least 18 years old and live in a home with someone who recently tested positive for COVID.

If allowed, it would be the first pill shown to treat COVID-19.

About Terry Gongora

Check Also

Strata Oncology Senior Vice President of Clinical Development Kat Kwiatkowski to Participate in Two Panels at the Precision Medicine World Conference

Title: Removing Barriers to Biomarker Testing Through Collaboration Time: Tuesday, June 28 at 9:00 a.m. …

Leave a Reply

Your email address will not be published.